Parsippany Chapter Upcoming Events Join PCCI

Member Profiles

 

Mahmoud Mahmoudian, PhD, FRSC

External Innovations, Strategic Partnerships

 

Dr. Mahmoudian is a Global Bio-Pharmaceutical Executive with a diverse career in big pharma (AZ, GSK, and Merck) and entrepreneurial biotech settings, including emerging markets.  He has extensive experience leading multi-national teams in R&D (drug discovery, preclinical development, phase I-III), operations, tech transfer,

 

manufacturing, and licensure.  Dr. Mahmoudian advances corporate development and research strategies by identifying external assets that complement an internal pipeline.  He has led cross-functional scientific due diligence teams to evaluate, recommend, and negotiate external innovation opportunities in products, technology platforms, or companies as acquisition targets in multi-million dollar deals.

 

Dr. Mahmoudian’s career spans 20 years in the biotechnology, pharmaceutical, and chemical sectors.  He joined Merck in 2007 with responsibility for External Partnerships in Vaccines, Biologics and BioVenture (biosimilars) on a global basis.  Prior to that, he was at Rohm & Haas as the Global Head of Biotechnology with responsibility for all strategic alliances and research in five sites (UK, France, Japan, China, USA) generating $600M sales.  Dr. Mahmoudian recruited to Eastman earlier in his career as the Worldwide Head of Biotechnology responsible for R&D, partnering, managing growth and development of its BioProducts portfolio.  He launched his career with GlaxoSmithKline, where he held a variety of research, technology, and management roles of increasing responsibility in drug discovery, preclinical development and BioPharm R&D.

 

Dr. Mahmoudian's key accomplishments include:

Establishing two biotech startups, at Eastman and Rohm & Haas, via partnerships and joint ventures (Genencor, Sanofi-Aventis).  Dr. Mahmoudian was a member of the CEO team that recommended divestiture of Genencor to Danisco for $475M. Serving as a Principal Investigator at GlaxoSmithKline on internal and in-licensed compounds for key strategic alliances that led to the discovery and development of six blockbusters with combined annual sales of $15B (Lamuvidine, anti-hepatitis; Epivir and Abacavir, anti-HIV; Relenza, anti-flu; Zygara, anti-leukaemic; and tribactam antibiotics). Managing Director (Alborz BioVentures), and an advisor to top international biopharma and life sciences venture capital firms on topics that include investment and research strategies, due diligence, business plans, portfolio analysis, technology and market assessments.

 

Dr. Mahmoudian earned his M.Sc. and Ph.D. in Biotechnology from Imperial College at the University of London, UK and was awarded a B.Sc. in Biochemistry / Human Physiology from the University of Newcastle, UK.  He currently serves on the International Editorial Advisory Board of seven scientific journals and is a Board member of the European Federation on Biotechnology.  Dr. Mahmoudian is an elected Fellow of the Royal Society of Chemistry (FRSC) and has >50 publications and patents to his name.

 

Dr. Mahmoudian is a dual US / British Citizen.  He and his family reside in Blue Bell, Pennsylvania.  A former marathoner, he now enjoys the active arts community in Philadelphia.

 

 

 

 

 

Contact Info:

Company:
Merck & Co. USA,

Vaccines & Biologics

Tel: (215) 620-3309

Email: mm6382@yahoo.co.uk
Web: www.linkedin.com/in/mahmoudian

 

Good Company! Good Drink! Good Food! Good Program! Good Fun!

 

Site Navigation

HOME  |  ABOUT PCCI  |   MAP / DIRECTIONS  |   JOIN US  |   BOARD MEMBERS  |   AFFILIATES  |  NEXT MEETING  |  ARCHIVES  |  PROFILES

CALENDAR OF EVENTS  |  PARSIPPANY CHAPTER  |  FEEDBACK / COMMENTS  |   CONTACT US

Pharmaceutical Consulting Consortium International, Inc.,

info@rxpcci.com or (610) 296-8086

Meetings Held at Embassy Suites - Valley Forge

888 Chesterbrook Blvd, Chesterbrook, Pennsylvania 19087

All content on this website is copyrighted and should not be reproduced without the consent of PCCI.

© Copyright 2016-2017

 

 

Tat Communication Inc